Gilead to cease late-stage research of Covid-19 therapy
A scientist at Gilead Sciences analyzes affected person antibody ranges on the Gilead laboratory in Foster Metropolis, California.
David Paul Morris | Bloomberg | Getty Photographs
Gilead Sciences mentioned on Monday it had determined to cease a late-stage trial of its intravenous therapy, Veklury, in high-risk non-hospitalized sufferers with Covid-19.
The corporate mentioned it not believes that growing a multiple-day injection that requires administration in a healthcare setting addresses an unmet want for non-hospitalized sufferers.
The choice to cease the research shouldn’t be as a consequence of efficacy or security considerations, Gilead mentioned.
Japan stocks lower at close of trade; Nikkei 225 down 0.50% By Investing.com
© Reuters. Japan stocks lower at close of trade; Nikkei 225 down 0.50% Investing.com – Japan stocks were lower after…
SocGen’s turnaround plan on track as it ups revenue forecast By Reuters
© Reuters. FILE PHOTO: A Societe Generale sign is seen outside a bank building in Paris, France, August 1, 2021….